Kit for detecting G873 site mutation of EGFR gene

Abstract

The invention relates to a kit for detecting G873 site mutation of an EGFR gene. The kit comprises a specific primer for detecting G873R (c.2617G>A) site mutation of the EGFR gene, the upstream primer nucleotide sequence of the specific primer is as shown in SEQ ID No.1, and the downstream primer nucleotide sequence of the specific primer is as shown in SEQ ID No.2. The close relationship between G873R (c.2617G>A) site mutation of the EGFR gene and the curative effect of post-operative adjuvant chemotherapy of the non-small cell lung cancer is revealed for the first time, the kit fordetecting site mutation of the EGFR gene is designed according to the discovery, and guidance is provided for individual adjuvant chemotherapy of the non-small cell lung cancer patient.

Description

Technical field [0001] The invention relates to a kit for detecting mutations at the G873R site of EGFR gene, which belongs to the fields of biotechnology and medical technology. Background technique [0002] EGFR is a tyrosine kinase receptor for cell proliferation and signal transduction. The receptor is a glycoprotein with a molecular weight of 170KDa. It penetrates the cell membrane and consists of an intracellular kinase domain, a transmembrane domain, and an extracellular ligand binding domain. . As a member of the epidermal growth factor receptor (HER) family, EGFR is widely distributed on the surface of epithelial cells, glial cells, keratinocytes, fibroblasts and other cell surfaces, and plays an important role in the physiological processes of cell growth, proliferation and differentiation. effect. Relevant studies have shown that high expression of EGFR has been found in many solid tumors, including lung cancer, kidney cancer, breast cancer, pancreatic cancer, and pr...

AI Technical Summary

Problems solved by technology

However, patients with non-small cell lung cancer who take EGFR-TKIs often fail due to drug resistance

Although the new generation of targeted drugs can overcome the drug resistance caused by mutations at the EGFR T790M site, 50% of non-small cell lung cancer patients with drug resistance still cannot obtain better therapeutic effects by taking EGFR-TKIs

Images